Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $117.00 at TD Cowen

Mirum Pharmaceuticals (NASDAQ:MIRM) had its target price hoisted by equities researchers at TD Cowen from $115.00 to $117.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen’s price target points to a potential upside of 24.18% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $130.00 price objective on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. HC Wainwright boosted their price objective on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Evercore restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Thursday. Finally, Leerink Partners reiterated an “outperform” rating and issued a $118.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $114.92.

Mirum Pharmaceuticals Trading Down 13.3%

Shares of NASDAQ MIRM traded down $14.40 during trading hours on Thursday, reaching $94.22. The stock had a trading volume of 1,266,554 shares, compared to its average volume of 770,760. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. The firm has a market cap of $4.84 billion, a price-to-earnings ratio of -108.89 and a beta of 0.49. The business’s fifty day moving average price is $92.67 and its two-hundred day moving average price is $78.81. Mirum Pharmaceuticals has a 52-week low of $36.88 and a 52-week high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.13). The firm had revenue of $148.93 million during the quarter, compared to analysts’ expectations of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.Mirum Pharmaceuticals’s quarterly revenue was up 49.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.00 earnings per share. Analysts expect that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Insider Activity at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt sold 1,053 shares of the stock in a transaction on Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $101,288.07. Following the sale, the chief financial officer owned 43,741 shares in the company, valued at $4,207,446.79. This represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jolanda Howe sold 968 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $99,994.40. Following the transaction, the senior vice president directly owned 4,503 shares of the company’s stock, valued at approximately $465,159.90. This trade represents a 17.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,136 shares of company stock worth $4,352,029 in the last quarter. 14.36% of the stock is owned by insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Mackenzie Financial Corp boosted its stake in shares of Mirum Pharmaceuticals by 425.2% in the fourth quarter. Mackenzie Financial Corp now owns 19,889 shares of the company’s stock worth $1,565,000 after buying an additional 16,102 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $3,179,000. Zacks Investment Management purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at approximately $2,401,000. Vestal Point Capital LP acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at $5,213,000. Finally, Virtus Investment Advisers LLC boosted its holdings in Mirum Pharmaceuticals by 16.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 10,513 shares of the company’s stock worth $830,000 after buying an additional 1,447 shares in the last quarter.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and strong product demand — Mirum reported ~49.8% y/y revenue growth to $148.9M driven by Livmarli and other bile‑acid medicines, beating top‑line estimates and cited by analysts as the main growth driver. Mirum’s Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
• Positive Sentiment: Analyst upgrade/price‑target lift from Stifel — Stifel raised its price target to $125 and kept a Buy rating, signaling continued analyst confidence in Mirum’s commercial momentum. Stifel Nicolaus price target raise (Benzinga)
• Positive Sentiment: Bullish market commentary — recent articles and transcripts emphasize strong secular growth and positive technical momentum, which can support upside if execution continues. Mirum Pharmaceuticals: Nothing Stops This Train (But The Technicals)
• Neutral Sentiment: RBC reiteration with slight PT cut — RBC trimmed its target from $130 to $128 but maintained an Outperform rating, calling recent weakness a potential buying opportunity. RBC note (StreetInsider)
• Neutral Sentiment: Citizens JMP trims target but stays constructive — target lowered to $132 with a Market Outperform rating, reflecting continued analyst belief in upside despite near‑term volatility. Citizens JMP price target change (Benzinga)
• Neutral Sentiment: FY‑2026 revenue guidance set to $630–$650M — the range overlaps Street estimates but the midpoint (~$640M) is just below some consensus figures, leaving room for debate on beat vs. miss as the year progresses. Business Wire: Q4 results & guidance
• Negative Sentiment: Q4 EPS missed — Mirum reported ($0.11) EPS vs. a $0.02 consensus (miss of $0.13), which pressured sentiment despite the revenue beat; the company still shows negative net margin and ROE metrics. MarketBeat: Q4 EPS miss
• Negative Sentiment: Mixed investor takeaway — the combination of an EPS miss, guidance that isn’t clearly above consensus, and high short‑term volatility likely explains the intraday pullback as investors re‑weigh near‑term profitability vs. longer‑term revenue growth. Zacks: Q4 loss, revenue beat

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.